How one global pharma team turned fragmented pricing data into strategic power. In a complex launch environment, pricing and market access teams face mounting pressure to deliver insights that resonate with CEOs, affiliates, payers, and investors. This case study reveals how a leading oncology organization partnered with EVERSANA to overcome data silos, manual reporting, and […]
In the world of pharmaceuticals, pricing strategy becomes especially critical after the loss of exclusivity (LOE) for blockbuster drugs. Once patent protection ends, competition from generics or biosimilars floods the market, leading to significant price erosion. However, there’s an opportunity that many companies overlook: leveraging tender data to maintain a competitive edge and optimize pricing […]
The pharmaceutical industry continues to face a multitude of changes that have the potential to directly impact launch strategy. From more recent tangible trends like a rise in cost-containment policies, to ongoing net price transparency forces and a focus on health equity, the potential to make mistakes during launch is growing. Reasons for traditional launch […]
The pharmaceutical industry faces a host of increasingly complex challenges and critical decisions when attempting to manage and predict their products’ plausible revenue patterns. The mishandling of revenue forecasting and evaluation can result in substantial financial liabilities, which has become more of an issue for manufacturers as products, disease states and additional factors that previously […]
EVERSANA’s Chris Lagoerio, Vice President, Revenue Management participated in a panel session, “Innovative Approaches to 340B Claims Data Identification,” at the Medicaid & Government Pricing Congress alongside fellow industry leaders Andrew Brownlee, Associate Director, Berkeley Research Group; Kathleen Black, Chairperson and Director, Government Operations, Pfizer Inc; and Cathy Burton-Meza, Senior Manager, Audits & Compliance, Gilead. […]
Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’ gross-to-net. But how and where to invest valuable assets is a significant decision. The process of revenue management, including […]
How Emerging Trends are Demanding a More Holistic View to Drive Maximum Value As the complexity of investments needed to secure patient access to therapy increases, so does the impact of these investments on a company’s net revenue. Each decision needs scrutiny, not only on its own merits and how it can affect patient access […]
The case for primary market research, Real-World Data (RWD), and deep healthcare experience combined to deliver targeted market access strategies. As diseases become more complex and market access becomes more restrictive, with multiple sources of market research and data analytic solutions available, pharmaceutical executives are often overwhelmed with various sources of information. Leaders must learn […]
NAVLIN Brief The European Commission has finally released its proposal to revise the European Union’s pharmaceutical legislation. The document includes proposals for a new Directive and a new Regulation, which revise and replace the existing pharmaceutical legislation via the largest reform in over 20 years The Commission proposes new incentives for AMR-related products, greater transparency […]
Biopharmaceutical companies have offered financial assistance for commercially covered patients’ out-of-pocket (OOP) cost sharing for 20+ years. However, in the ongoing evolution of controlling versus encouraging patient access to specific drugs, payers and biopharma also have a long history of one-upmanship. Are pharma motivations for offering copay assistance centered on the patient, their own bottom […]
Why Develop a Specialty Pharmacy Network Strategy? Specialty pharmaceuticals often require high-touch, labor-intensive services to expedite patient access and improve therapy adherence. Additionally, patients requiring specialty therapies are often medically complex and challenging to manage. These factors highlight the need to identify SP network partners with the proper expertise to achieve optimal product distribution and […]
‘PBM-lead GPO,’ a Newly Created Term to Describe Large Scale PBM-Owned Rebate Aggregators PBM-led group purchasing organizations (GPOs) are not true group purchasing organizations in scope, nor are they pure rebate aggregators. Rather, PBM-lead GPOs are organizations formed by PBMs with one or more members, whose primary purpose is to aggregate purchasing volume to negotiate […]
